Gyros and Tekon Biotech Sign Distribution Agreement
News Apr 01, 2014
Gyros AB has announced that it has appointed Tekon Biotech as exclusive distributor of its nanoliter-scale immunoassay platform Gyrolab™ xP in China, Taiwan & Hong Kong. Tekon Biotech is a leading distributor to pharmaceutical, biotechnology and academic laboratories.
Gyros’ immunoassay platform (www.gyros.com) is used by major biopharmaceutical companies and their service providers worldwide to improve productivity and efficiency during the development of biotherapeutics and vaccines, boosting time-critical workflows and helping to meet regulatory demands.
The platform comprises Gyrolab xP workstation, control and evaluation software, and the unique microfluidic Gyrolab Bioaffy CDs in which immunoassay steps are integrated and run at nanoliter scale.
“We are impressed with Tekon’s reputation for service and technical support in the region, and with a customer base including all major pharmaceutical and biotechnology companies in China, as well as the top 50 universities, Tekon is an ideal partner,” said Dan Calvo, CEO, Gyros AB. “The acceptance of our nanoliter-scale immunoassay platform continues to grow within the global biopharmaceutical industry, and we are delighted that Tekon will be helping to build our network of customers in China, Taiwan and Hong Kong.”
“We are excited to represent Gyros in China," said David Hadfield, CEO, Tekon Biotech in Shanghai. “With the tremendous growth in Biologics in China, plus increased demand for PK/PD and ADA testing, we see great potential for the Gyrolab platform and it’s advances in miniaturized, automated immunoassays.”
Innate Reaction of Hematopoietic Stem Cells to Severe InfectionsNews
Researchers at the University of Zurich have shown for the first time that hematopoietic stem cells detect infectious agents themselves and begin to divide, without signals from growth factors.READ MORE
Cow Antibodies Yield Important Clues For Developing A Broadly Effective AIDS VaccineNews
The unexpected animal model is providing clues for important questions at a moment when new energy has infused HIV vaccine research.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Transgenic Animals - Micromanipulation Techniques
Apr 10 - Apr 11, 2018
EMBO Practical Course: Extracellular Vesicles: From Biology to Biomedical Applications
Apr 09 - Apr 13, 2018
EMBO | EMBL Symposium: Tissue Self-Organisation: Challenging the Systems
Mar 11 - Mar 14, 2018
EMBL Course: Brillouin Microscopy: Emerging Tool for Probing Mechanical Properties of Living Cells
Jan 17 - Jan 19, 2018